Dr. J. Keith Joung is a foremost expert on designer gene-editing tools and assessing and improving their safety. He currently holds the Robert B. Colvin, M.D., Endowed Chair in Pathology and is a pathologist at Massachusetts General Hospital, and a professor of pathology at Harvard Medical School. Keith has received numerous awards, including the 2022 Samsung Ho-Am Prize in Medicine, an NIH Director’s Pioneer Award, an NIH Director’s Transformative Research Project R01 Award, an NIH R35 MIRA (Maximizing Investigators Research Award), and election into the American Association of University Pathologists. He serves on the editorial boards of Cell Genomics, Human Gene Therapy, Genome Biology, and Trends in Biotechnology. He has co-founded and continues to advise multiple biotechnology companies, including Beam Therapeutics, Chroma Medicine, Editas Medicine, Nvelop Therapeutics, Pairwise Plants, and SeQure Dx. 

Keith holds a Ph.D. in Genetics from Harvard University, an M.D. from Harvard Medical School, and an A.B. in Biochemical Sciences from Harvard College.